Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01) | JOURNAL OF CLINICAL ONCOLOGY |